L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol stimulates ganglioside biosynthesis, neurite outgrowth and synapse formation in cultured cortical neurons, and ameliorates memory deficits in ischemic rats.
To address the role of brain gangliosides in synaptic plasticity, the synthetic ceramide analog, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) was used to manipulate the biosynthesis of gangliosides in cultured cortical neurons. Spontaneous synchronized oscillatory activity of intracellular Ca2+ between the neurons, which represents synapse formation, was suppressed by the depletion of endogenous gangliosides by D-threo-PDMP, an inhibitor of glucosylceramide synthase. The decreased functional synapse formation was normalized by supplementation of GQ1b but not by the other gangliosides, suggesting that de novo synthesis of ganglioside GQ1b is essential for the synaptic activity (Mizutani A. et al., Biochem. Biophys. Res. Commun. 222, 494-498, 1996). On the other hand, the enantiomer of the inhibitor, L-threo-PDMP, could elevate cellular levels of glycosphingolipids including gangliosides. This paper presents our recent findings on the neurotrophic actions of L-threo-PDMP in vitro and in vivo. We found that L-PDMP could up-regulate neurite outgrowth, functional synapse formation and ganglioside biosynthesis through activating GM3, GD3 and GQ1b synthases. Simultaneously, the activity of p42 mitogen-activated protein kinase was also facilitated by L-PDMP. To evaluate the efficacy of this drug on long term memory, rats were trained for 2 weeks using an 8-arm radial maze task, and then forebrain ischemia was induced by 4-vessel occlusion (for 10 min x 2 with a 60 min interval). Repeated treatment of L-threo-PDMP (40 mg/kg, i.p. for 6 days, twice a day) starting 24 h after the ischemia, improved the deficit of the well-learned spatial memory, demonstrating the potential therapeutic use of the ceramide analog for treatment of neurodegenerative disorders.
Inokuchi
J
J
Seikagaku Corporation, Tokyo Research Institute, Higashiyamato, Japan. inokuchi@kinou02.pharm.hokudai.ac.jp
Kuroda
Y
Y
Kosaka
S
S
Fujiwara
M
M
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D002540:Cerebral Cortex / Q000166:cytology* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005732:Gangliosides / Q000096:biosynthesis*; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors; D009025:Morpholines / Q000494:pharmacology*; D016501:Neurites / Q000187:drug effects* / Q000648:ultrastructure; D051381:Rats; D017208:Rats, Wistar
D004791:Enzyme Inhibitors; D005732:Gangliosides; D009025:Morpholines; C033110:RV 538; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase